1. T-cell involvement in delayed-type hypersensitivity reactions to infliximab 
Maria Jose Torres, MD, PhD, Patrícia Chaves, PhD, Inmaculada Doña, MD, Natalia Blanca-López, MD, PhD, Gabriela Canto, MD, PhD, Cristobalina Mayorga, PhD, Miguel Blanca, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 128, Issue 6, Pages e1 (December 2011)
DOI: /j.jaci
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Hematoxilin and eosin and immunohistochemical analysis of different markers, CD3, CD4, CD8, CD57, HLA-DR, CD45, CD45RO, granzyme B, and perforin, in a skin biopsy obtained from the acute reaction produced by the DPT in patient 1.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Sequential measurement of different markers (CD3, CD4, CD8, CD56, granzyme B, perforin, HLA-DR, CLA, CXCR3, CCR10) in PBMCs. Results are expressed as means of percentage of cells from cases 1 and 2. T1 indicates samples obtained at the acute phase, T2 5 days later, and basal 30 days after symptoms disappeared.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig E1
Bars express mean of percentage of CFSEdim cells stained with anti-CD3 and CD56 MoAb from the 2 patients and 5 controls of the LTT using infliximab at different concentrations (10, 1, and 0.1 mg/mL), negative controls (lymphocytes alone), and positive controls (tetanus toxoid and LPS).
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions